SLC1A1 and Parkinson disease: Notably, the beneficial effects of glutamate were completely lost when the expression of either Excitatory Amino Acid Transport 3 (EAAT3) or NCX1 was silenced, highlighting the functional correlation between EAAT3 and NCX1 and the potential of targeting EAAT3/NCX1 function to mitigate PD pathology, as it facilitates glutamate uptake and metabolic utilization in dopaminergic neurons [72].